Instrument Inactif

Communiqués Vital Therapies Inc Nasdaq

Actions

US92847R1041

Recherche biotechnologique et médicale

Communiqués

11/08	Immunic: Q2 Earnings Snapshot	AQ
11/08	Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update	PR
10/08	Immunic Appoints Elena Ridloff to Board of Directors	PR
09/07	Immunic to Participate in Investor Conferences in July	PR
10/06	Immunic to Participate in Investor, Industry and Scientific Conferences in June	PR
01/06	Immunic : Presentation (20260601 Immunic Company Overview June 2026)	PU
28/05	Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis	PR
27/05	Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer	PR
19/05	Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors	PR
13/05	Immunic : Q1 2026 News Release	PU
13/05	Immunic : Presentation (20260513 Immunic Company Overview May 2026)	PU
13/05	Immunic: Q1 Earnings Snapshot	AQ
13/05	Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update	PR
30/04	Immunic to Participate in Investor and Medical Conferences in May	PR
28/04	Immunic : Presentation (20260428 Immunic Company Overview April 2026)	PU
28/04	Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer	PR
23/04	Immunic, Inc. Announces 1-for-10 Reverse Stock Split	EQ
23/04	Immunic, Inc. Announces 1-for-10 Reverse Stock Split	PR
09/04	Immunic to Participate in Scientific and Medical Conferences in April	EQ
09/04	Immunic to Participate in Scientific and Medical Conferences in April	PR
01/04	Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement	EQ
01/04	Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement	PR
31/03	Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton	EQ
31/03	Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton	PR
10/03	Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium	EQ